Live
- Young Kabaddi Player Dies of Heart Attack During Match in Mandya
- Exciting Return of Santosh Trophy Football Tournament Kicks Off in Hyderabad
- Head Constable Dies by Suicide, Cites harssament by wife and inlaws
- Delhi BJP claims AAP govt will never pay women allowance like in Punjab
- India is 'Mother of Democracy': PM Modi
- ‘One nation, one election’ will undermine India’s federal structure: Mehbooba Mufti
- Vikram collaborates with director Madon Ashwin for ‘Chiyaan63’
- ‘Bachhala Malli’ trailer heightens anticipation
- Karnataka quota row: Backward Class forum chief warns Lingayat seer over 'tinkering with reservations'
- Tight security arrangements at Group-II examination centers District SP
Aurobindo Pharma, Covaxx To Develop Covid-19 Vaccine For India, UNICEF
Covid-19 vaccine
Aurobindo Pharma and US-based Covaxx have entered into a license agreement to develop, commercialise and manufacture a vaccine to fight Covid-19 for India and the United Nations Children's Fund (UNICEF) agency.
Hyderabad (Telangana): Aurobindo Pharma and US-based Covaxx have entered into a license agreement to develop, commercialise and manufacture a vaccine to fight Covid-19 for India and the United Nations Children's Fund (UNICEF) agency.
Covaxx is currently conducting a phase one clinical trial for the vaccine candidate UB-61.
"We are proud to partner with Covaxx in developing the first-ever synthetic peptide-based vaccine to combat the Covid-19 pandemic," said N Govindarajan, Managing Director of Aurobindo Pharma.
"This vaccine has immense potential in eliminating shedding and hence containing the spread of pandemic," he said in a statement on Thursday.
Aurobindo has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June next year.
Under the signed agreement, Aurobindo has obtained exclusive rights to develop, manufacture and sell Covaxx's UB-612 vaccine in India and to UNICEF as well as non-exclusive rights in other select emerging and developing markets.
